Suppression of antitumour protective cytotoxic T lymphocyte responses to a human papillomavirus 16 E7 DNA vaccine by coinjection of interleukin-12 complementary DNA: Involvement of nitric oxide in immune suppression

Immunology

Volumn 128, Issue 1 PART 2, 2009, Pages

  Sin, Jeong Im ^a  

^a Catholic University of Daegu   (South Korea)

Author keywords

Cervical cancer; DNA vaccines; Human papillomavirus; Immune suppression; Interferon ; Interleukin 12; Nitric oxide

Indexed keywords

COMPLEMENTARY DNA; DNA VACCINE; INTERLEUKIN 12; NITRIC OXIDE; PROTEIN E7; WART VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DNA IMMUNIZATION; DRUG POTENTIATION; FEMALE; HELPER CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOMODULATION; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DNA, COMPLEMENTARY; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NITRIC ACID; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; T-LYMPHOCYTES, CYTOTOXIC; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA;

EID: 68249142911     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2009.03068.x     Document Type: Article

References (35)

1. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991 184 : 9 13.
2. Scheffner M, Munger K, Bryne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci U S A 1991 88 : 5523 7.
3. Werness BA, Levine AJ, Howley PM. Association of HPV type 16 and 18 E6 protein with p53. Science 1990 248 : 76 9.
4. Dyson N, Howley PM, Munger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind the retinoblastoma gene product. Science 1989 243 : 934 7.
5. Sin JI. Human papillomavirus vaccines for the treatment of cervical cancer. Expert Rev Vaccines 2006 5 : 783 92.
6. Sin JI. Promises and challenges of human papillomavirus vaccines for cervical cancer. Expert Rev Anticancer Ther 2009 9 : 1 5.
7. Kim TW, Hung CF, Ling M, Juang J, He L, Hardwick JM, Kumar S, Wu TC. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. J Clin Invest 2003 112 : 109 17.
8. Kim TW, Hung CF, Boyd DA, He L, Lin CT, Kaiserman D, Bird PI, Wu TC. Enhancement of DNA vaccine potency by coadministration of a tumor antigen gene and DNA encoding serine protease inhibitor-6. Cancer Res 2004 64 : 400 5.
9. Kim MS, Sin JI. Both antigen optimization and lysosomal targeting are required for enhanced anti-tumour protective immunity in a human papillomavirus E7-expressing animal tumour model. Immunology 2005 116 : 255 66.
10. Sin JI, Hong SH, Park YJ, Park JB, Choi YS, Kim MS. Antitumor therapeutic effects of E7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of E7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes. DNA Cell Biol 2006 25 : 277 86.
11. Sin JI, Kim JJ, Boyer JD, Higgins TJ, Ciccarelli RB, Weiner DB. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model. J Virol 1999 73 : 501 9.
12. Sin JI, Kim JJ, Arnold RL et al. Interleukin-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 type CD4+ T cell mediated protective immunity against HSV-2 challenge. J Immunol 1999 162 : 2912 21.
13. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB. In vivo engineering of a cellular immune response by co-administration of IL-12 expression vector with a DNA immunogen. J Immunol 1997 158 : 816 26.
14. Iwasaki A, Stiernholm BJ, Chan AK, Berstein NL, Barber BH. Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. J Immunol 1997 158 : 4591 601.
15. Yu WG, Ogawa M, Mu J, Umehara K, Tsujimura T, Fujiwara H, Hamaoka T. IL-12-induced tumor regression correlates with in situ activity of IFN-gamma produced by tumor-infiltrating cells and its secondary induction of anti-tumor pathways. J Leukoc Biol 1997 62 : 450 7.
16. Dias S, Thomas H, Balkwill F. Multiple molecular and cellular changes associated with tumor stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer 1998 75 : 151 7.
17. Robertson MJ, Soiffer RJ, Wolf SF, Manley TJ, Donahue C, Young D, Hermann SH, Ritz J. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992 175 : 779 88.
18. Kobayashi M, Fitz L, Ryan M et al. Identification and purification of natural killer cell stimulator factor (NKSF): a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989 170 : 827 45.
19. Germann T, Gately MK, Schoenhaut DS et al. Interleukin-12/T cell stimulating factor, a cytokine with multiple effects on T helper type 1 (Th1) but not on Th2 cells. Eur J Immunol 1993 23 : 1762 70.
20. Kim TY, Myoung HJ, Kim JH, Moon IS, Kim TG, Ahn WS, Sin JI. Both E7 and CpG-ODN are required for protective immunity against challenge with human papillomavirus 16 (E6/E7)-immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Cancer Res 2002 62 : 7234 40.
21. Kim TG, Kim CH, Won EH, Bae SM, Ahn WS, Park JB, Sin JI. CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific anti-tumor immunity in a HPV 16 (E6/E7)-associated tumor animal model. Immunology 2004 112 : 117 25.
22. Ahn WS, Bae SM, Kim TY, Kim TG, Lee JM, Namkoong SE, Kim CK, Sin JI. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum Gene Ther 2003 14 : 1389 99.
23. Ye GW, Park JB, Park YJ, Choi YS, Sin JI. Increased sensitivity of radiated murine cervical cancer tumors to E7 subunit vaccine-driven CTL-mediated killing induces synergistic antitumor activity. Mol Ther 2007 15 : 1564 70.
24. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993 23 : 2242 9.
25. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther 2002 13 : 553 68.
26. Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, Wu TC. Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001 61 : 3698 703.
27. Lamikanra A, Pan ZK, Isaacs SN, Wu TC, Paterson Y. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J Virol 2001 75 : 9654 64.
28. Chen H-W, Pan C-H, Huann H-W, Liau M-Y, Chiang J-R, Tao MH. Suppression of immune response and protective immunity to a Japanese encephalitis virus DNA vaccine by coadministration of an IL-12-expressing plasmid. J Immunol 2001 166 : 7419 26.
29. Lasarte JJ, Corrales FJ, Casares N, Lopez-Diaz de Cerio A, Qian C, Xie X, Borras-Cuesta F, Prieto J. Different doses of adenoviral vector expressing IL-12 enhance or depress the immune response to a coadministered antigen: the role of nitric oxide. J Immunol 1999 162 : 5270 7.
30. Suh Y-S, Ha S-J, Lee C-H, Sin JI, Sung YC. Enhancement of VP1-specific immune responses and protection against EMCV-K challenge by codelivery of VP1 with IL-12 plasmid DNAs. Vaccine 2001 19 : 1891 8.
31. Bermudez-Humaran LG, Cortes-Perez NG, Lefevre F et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J Immunol 2005 175 : 7297 302.
32. Yoon HA, Aleyas AG, George JA et al. Modulation of immune responses induced by DNA vaccine expressing glycoprotein B of Pseudorabies virus via coadministration of IFN-β-associated cytokines. J Interferon Cytokine Res 2006 26 : 730 8.
33. Mazzolini G, Narvaiza I, Perez-Diez A et al. Genetic heterogeneity in the toxicity to systemic adenoviral gene transfer of interleukin-12. Gene Ther 2001 8 : 259 67.
34. Orange JS, Wolf SF, Biron CA. Effects of IL-12 in the responses and susceptibility to experimental viral infections. J Immunol 1994 152 : 1253 64.
35. Tartaglia LA, Ayres TM, Wong GH, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993 74 : 845 53.